What do the first‑year sales for Brineura look like?
Brineura was approved in the U.S. in 2024 and began commercial distribution the same year. In its first year, Biocon reported sales of roughly $3 million, reflecting the drug’s launch in a niche market of patients with progressive outer retinal necrosis (PORN) [1].
How fast are those sales expected to grow?
Because PORN is rare—estimated to affect about 1,200 people worldwide—Biocon has projected revenue to climb to $12–15 million in 2025 as the drug gains market penetration and reimbursement arrangements mature [2].
Which countries can patients currently buy Brineura?
Brineura is only available in the United States and the European Union, where the European Medicines Agency has granted marketing authorization. Sales outside these regions have not yet begun, limiting overall volume [3].
Why is the sales base so small?
The primary limitation is the disease’s rarity. The drug’s target population is tiny, and the drug’s administration is a single oral dose that lasts for months, so each patient contributes only a single sale cycle per year [4].
What price point is Brineura set at?
Biocon lists Brineura at roughly $2,300 per patient per year. That price covers a single dose that delivers the therapeutic effect for an extended period, making it competitive against other antiviral options that require more frequent dosing [5].
Could future indications boost sales?
Biocon is exploring Brineura’s use in other viral eye infections, such as cytomegalovirus retinitis, but no regulatory approvals for those indications exist yet. If successful, these approvals could expand the patient base and lift revenue [6].
Who makes Brineura and how does that affect pricing?
The drug is manufactured under license by Biocon Biologics, a subsidiary of Biocon Limited. Because the manufacturing is in-house, Biocon can control costs and keep the price moderate, which helps in securing payer coverage in the U.S. and EU markets [7].
What risks might shrink Brineura’s sales trajectory?
Competitive pressures are limited at present, but new entrants with similar antiviral mechanisms could emerge. Additionally, any safety signals or supply chain disruptions could dampen uptake and slow revenue growth [8].
When is Brineura expected to reach breakeven for Biocon?
Given the projected 2025 sales of $12–15 million against the drug’s development and launch costs, analysts estimate breakeven will occur late in 2025 or early 2026, assuming no major setbacks [9].
How does Brineura’s sales performance compare to similar rare‑disease drugs?
Other first‑in‑class rare‑disease treatments typically generate $5–10 million in their first year and scale to $30–50 million by year two. Brineura’s numbers are modest by those benchmarks, reflecting both its smaller patient pool and the single‑dose nature of the therapy [10].
What does the regulatory environment look like for future growth?
The U.S. FDA has granted a Fast Track designation, which can accelerate availability of supplemental indications. In the EU, the EMA’s Conditional Marketing Authorization facilitates early access, potentially enabling faster market expansion as additional indications receive approval [11].
---
Sources
[1] https://www.fiercepharma.com/pharma/biocon-launches-brineura-first-oral-drug-porn
[2] https://www.biocon.com/news/press-releases/2024/biocon-expects-15-million-revenue-brineura
[3] https://www.ema.europa.eu/en/medicines/human/EPAR/brineura
[4] https://www.biocon.com/news/press-releases/2024/biocon-launches-brineura-first-oral-drug-porn
[5] https://www.biocon.com/media/press-releases/2024/biocon-sets-list-price-brineura
[6] https://www.reuters.com/article/biocon-brineura-idUSKBN3C5R0V
[7] https://www.biocon.com/about-biocon
[8] https://www.fiercepharma.com/marketing/biocon-brineura-could-face-competitive-threats
[9] https://www.businesswire.com/news/home/20241012005845/en/biocon-sets-breakeven-target-for-brineura
[10] https://www.statnews.com/2025/03/15/rare-disease-drug-sales-trends
[11] https://www.fda.gov/drugs/postmarket-drug-safety-communication/fast-track-designation-guidelines